ConductScience.org, home

Paper42467272

Bacteria mediated tumor therapy recent advances challenges and future perspectives.

Mao W and 1 other. Discov Oncol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Bacteria mediated tumor therapy recent advances challenges and future perspectives. Papers, record 42467272. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42467272

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bacteria mediated tumor therapy recent advances challenges and future perspectives.
PubMed
Journal
Discov Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mao WWeihong
2Deng CChunmin

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
SYWD2024238Medical Innovation Application Research of Suzhou Science and Technology BureauPubMed
QNXM2024091Scientific research project of Suzhou Municipal Health CommissioPubMed

Source PubMed

Download CSV of grants

References86

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134575965Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.Int J Mol Sci2021https://conductscience.org/library/papers/34575965PubMed
235403784Decorating Bacteria with Triple Immune Nanoactivators Generates Tumor-Resident Living Immunotherapeutics.Angew Chem Int Ed Engl2022https://conductscience.org/library/papers/35403784PubMed
341083007Transdermal hydrogen therapy for psoriasis using cavity-embedded double-conical microneedles.J Control Release2025https://conductscience.org/library/papers/41083007PubMed
439089313Radiotherapy, immunity, and immune checkpoint inhibitors.Lancet Oncol2024https://conductscience.org/library/papers/39089313PubMed
537129253Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine.ACS Nano2023https://conductscience.org/library/papers/37129253PubMed
634534860Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery.Biomaterials2021https://conductscience.org/library/papers/34534860PubMed
741155984Engineered Bacteria-Nano Hybrid System: The Intelligent Drug Factory for Next-Generation Cancer Immunotherapy.Pharmaceutics2025https://conductscience.org/library/papers/41155984PubMed
838219524Engineering bacteria for cancer immunotherapy.Curr Opin Biotechnol2024https://conductscience.org/library/papers/38219524PubMed
935609407Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses.Biomaterials2022https://conductscience.org/library/papers/35609407PubMed
1038909699Manganese-induced Photothermal-Ferroptosis for Synergistic Tumor Therapy.J Control Release2024https://conductscience.org/library/papers/38909699PubMed
1139093127Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.Clin Cancer Res2024https://conductscience.org/library/papers/39093127PubMed
1239051784The Rational Engineered Bacteria Based Biohybrid Living System for Tumor Therapy.Adv Healthc Mater2024https://conductscience.org/library/papers/39051784PubMed
1340953609Antisense oligonucleotide-loaded nanozyme reverses tumor immune suppression through sonogenetic metabolic therapy.J Control Release2025https://conductscience.org/library/papers/40953609PubMed
1438987493Preparation of environmentally responsive PDA&DOX@LAC live drug carrier for synergistic tumor therapy.Sci Rep2024https://conductscience.org/library/papers/38987493PubMed
1541128615Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives.Protein Cell2026https://conductscience.org/library/papers/41128615PubMed
1640532565Nanozymes for regulation of reactive oxygen species in biomedical applications: Design, enzyme-like activity and therapeutic mechanisms.Colloids Surf B Biointerfaces2025https://conductscience.org/library/papers/40532565PubMed
1739984501Oral delivery of therapeutic proteins by engineered bacterial type zero secretion system.Nat Commun2025https://conductscience.org/library/papers/39984501PubMed
1840480220Cellular mechanisms underlying beneficial versus detrimental effects of bacterial antitumor immunotherapy.Immunity2025https://conductscience.org/library/papers/40480220PubMed
1932483165Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity.Nat Commun2020https://conductscience.org/library/papers/32483165PubMed
2040846311Recent Advances in Nanomedicine for Modulating Intratumoral Bacteria in Cancer Therapy.Mol Pharm2025https://conductscience.org/library/papers/40846311PubMed

See all 86 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42467272

GET https://conductscience.org/api/papers/v1/42467272/references?page=2